The increasingly popular class of GLP-1 receptor and GIP dual medications, including tirzepatide, semaglutide, and the newly introduced retatrutide, provide significant progress in diabetes management . https://research-peptides-usa765068.aioblogs.com/96470515/tirzepatide-a-comparative-look